Menu Search
Equities

Navamedic ASA

NAVA:OSL

Navamedic ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)25.90
  • Today's Change-0.80 / -3.00%
  • Shares traded7.33k
  • 1 Year change-29.81%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in NOK

The 2 analysts offering 12 month price targets for Navamedic ASA have a median target of 37.00, with a high estimate of 38.00 and a low estimate of 36.00. The median estimate represents a 42.86% increase from the last price of 25.90.
High46.7%38.00
Med42.9%37.00
Low39.0%36.00

Earnings history & estimates in NOK

On Aug 16, 2024, earnings of 1.15 per share. This result exceeded the 0.91 consensus of the 2 analysts covering the company
The next earnings announcement is expected on Feb 17, 2025.
Average growth rate-355.00%
Navamedic ASA reported annual 2023 earnings of 0.221 per share on Feb 15, 2024.
Average growth rate+2,153.84%
More ▼

Revenue history & estimates in NOK

Navamedic ASA had 3rd quarter 2024 revenues of 123.06m. This missed the 138.50m consensus estimate of the 2 analysts following the company. This was 1.05% above the prior year's 3rd quarter results.
Average growth rate-1.66%
Navamedic ASA had revenues for the full year 2023 of 512.00m. This was 33.98% above the prior year's results.
Average growth rate+120.35%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.